This is a low-impact academic collaboration with no disclosed funding or milestones. ATYR2810 remains preclinical; the next catalyst is likely a clinical trial initiation, which has not been announced. Monitor for IND filing or partnership expansion.
Price Chart
Executive Summary
aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine to further develop ATYR2810, its anti-NRP2 monoclonal antibody, in pediatric osteosarcoma. The collaboration is preclinical and involves no disclosed financial terms, making it a routine academic partnership with no immediate revenue or catalyst impact.
Key Facts
- Collaboration with Albert Einstein College of Medicine to develop ATYR2810 in pediatric osteosarcoma
- ATYR2810 is a fully humanized monoclonal antibody targeting NRP2, currently in preclinical development
- No financial terms, milestones, or funding amounts disclosed
- Pediatric osteosarcoma: ~1,000 new U.S. cases/year; ~40% relapse rate
- ATYR2810 has completed GLP toxicology and cGMP manufacturing
Financial Impact
No financial terms disclosed; preclinical collaboration with no near-term revenue impact
Risk Factors
- ATYR2810 is preclinical; no guarantee of clinical success or regulatory approval
- No disclosed financial commitment from either party; collaboration may not advance to clinical stage
- aTyr's primary focus remains efzofitimod in interstitial lung disease; ATYR2810 is a secondary asset
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383277 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $0.1717 $0.1534 | ▼ −10.66% | ▼ −10.51% | $0.1530 (−10.89%) |
Oct 7, 2026 19d ago | SC 13G/A | $0.2783 $0.1833 | ▼ −34.14% | ▼ −33.16% | $0.1530 (−45.02%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.3564 $0.3077 | ▲ +13.66% | ▲ +12.48% | $0.1530 (+57.07%) |
Aug 7, 2026 11w ago | 8-K | $0.5289 $0.5189 | ▲ +1.89% | ▲ +1.84% | $0.1530 (+71.07%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.4754 $0.4629 | ▼ −2.63% | ▼ −3.06% | $0.1530 (−67.82%) |
Jun 8, 2026 20w ago | 8-K | $0.4556 $0.4433 | ▲ +2.70% | ▲ +5.11% | $0.1530 (+66.42%) |
Jun 1, 2026 21w ago | 8-K | $0.5200 $0.4560 | ▼ −12.31% | ▼ −9.34% | $0.1530 (−70.58%) |
May 15, 2026 23w ago | 8-K | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 15, 2026 23w ago | Press Release | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 11, 2026 24w ago | 8-K | $0.5300 $0.5200 | ▼ −1.89% | ▼ −1.96% | $0.1530 (−71.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers